Ownership and insider activity for Phathom Pharmaceuticals, Inc. (PHAT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada.
Price
| Price | $7.69 |
| Market Cap | $622M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-03 | Breedlove Robert Charles | F-InKind | 460 | $4K |
| 2026-07-14 | Breedlove Robert Charles | F-InKind | 1,555 | $17K |
| 2026-05-22 | Parikh Asit | G-Gift | 28,000 | |
| 2026-05-22 | Parikh Asit | G-Gift | 28,000 | |
| 2026-05-20 | Parikh Asit | M-Exempt | 17,500 | $87K |
| 2026-05-19 | Parikh Asit | A-Award | 24,122 | |
| 2026-05-20 | Parikh Asit | D-Return | 17,500 | $87K |
| 2026-05-19 | Topper James N | A-Award | 24,122 | |
| 2026-05-19 | Stenhouse Mark | A-Award | 24,122 | |
| 2026-05-19 | FIELDS HEIDI | A-Award | 24,122 |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $879000 | $243.8M | $287.5M | $183.3M | $155.4M | $381.4M | $297.3M | $130.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | $82000 | 0 | 0 | $1.6M | $38.8M | $78.1M |
| Inventory | 0 | 0 | -$82000 | 0 | 0 | $1.2M | $3.2M | $5.5M |
| Total Current Assets | $902000 | $255.6M | $291.4M | $186.5M | $160.5M | $397.4M | $360.1M | $229.0M |
| Property, Plant & Equipment | 0 | $1.4M | $3.4M | $2.6M | $3.5M | $3.6M | $2.1M | $3.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $902000 | $257.2M | $295.1M | $189.4M | $164.8M | $413.8M | $378.3M | $259.1M |
| Accounts Payable | $55000 | $699000 | $16.8M | $5.2M | $10.0M | $12.6M | $10.5M | $5.0M |
| Short-term Debt | $1.9M | 0 | $7.4M | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.2M | $3.7M | $55.5M | $18.9M | $26.2M | $38.8M | $85.7M | $132.0M |
| Long-term Debt | 0 | $22.8M | $39.6M | $89.7M | $95.3M | $137.8M | $201.4M | $209.1M |
| Total Liabilities | $2.2M | $29.2M | $100.8M | $117.3M | $239.6M | $486.6M | $631.9M | $697.3M |
| Retained Earnings | -$1.3M | -$256.4M | -$385.5M | -$529.4M | -$727.1M | -$928.7M | -$1.26B | -$1.48B |
| Total Equity | -$1.3M | $228.0M | $194.3M | $72.2M | -$74.8M | -$72.8M | -$253.6M | -$438.2M |
| Total Debt | $1.9M | $23.6M | $49.0M | $91.3M | $97.1M | $139.0M | $201.9M | $211.8M |
| Net Debt | $1.1M | -$220.2M | -$238.5M | -$91.9M | -$58.3M | -$242.4M | -$95.4M | $81.8M |
| Working Capital | -$1.3M | $251.9M | $235.8M | $167.6M | $134.3M | $358.7M | $274.4M | $96.9M |
Financial Health
| Debt / Equity | -0.49 |
| Current Ratio | 1.92 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -7.89 |
Profitability
| Return on Equity | 25.70% |
| Return on Invested Capital | -23.36% |
| Return on Assets | -30.29% |
| Gross Margin | 82.92% |
| Operating Margin | -16.96% |
| Net Margin | -41.34% |
Related companies: ANAB · BBOT · BCAX · KOD · NRIX · OCS · SANA
Explore sector: Healthcare · Biotechnology
More sections of PHAT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks